1/31/2014 9:10:23 AM
TEL AVIV, Israel, Jan. 31, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City on February 10-11, 2014. The Alcobra presentation is on Monday, February 10 at 3:30pm Eastern Time.
Help employers find you! Check out all the jobs and post your resume.
comments powered by